AKBA
Akebia Therapeutics, Inc.NASDAQHealthcare$1.38-2.13%ClosedMarket Cap: $369.7M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
10.74
P/S
1.50
EV/EBITDA
17.72
DCF Value
$-4.11
FCF Yield
19.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
83.3%
Operating Margin
9.9%
Net Margin
-2.3%
ROE
-16.7%
ROA
-1.4%
ROIC
9.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $57.6M | 78.8% | $-8.6M | $-12.2M | $-0.05 | — |
| FY 2025 | $236.2M | 83.3% | $23.5M | $-5.3M | $-0.02 | — |
| Q3 2025 | $58.8M | 83.5% | $4.4M | $540.0K | $0.00 | — |
| Q2 2025 | $62.5M | 84.1% | $14.1M | $247.0K | $0.00 | — |
| Q1 2025 | $57.3M | 86.7% | $13.5M | $6.1M | $0.03 | — |
| Q4 2024 | $46.5M | 56.2% | $-14.3M | $-22.8M | $-0.10 | — |
| FY 2024 | $160.2M | 60.6% | $-50.5M | $-69.4M | $-0.33 | — |
| Q3 2024 | $37.4M | 62.2% | $-12.5M | $-20.0M | $-0.10 | — |
| Q2 2024 | $43.6M | 81.0% | $-8.7M | $-8.6M | $-0.04 | — |
| Q1 2024 | $32.6M | 91.7% | $-14.9M | $-18.0M | $-0.09 | — |
| Q4 2023 | $56.2M | 66.8% | $1.4M | $614.0K | $0.00 | — |
| FY 2023 | $194.6M | 61.9% | $-46.3M | $-51.9M | $-0.28 | — |